Thursday, April 18, 2024 5:00:43 PM
Below was in the First Attorneys Letter
Different than the Amended Letter
No Reliance by Other Persons. No person or entity other than OTC Markets Group is entitled to rely upon
this Opinion of Counsel. OTC Markets Group, however, is granted full and complete permission and rights to publish
this document via the OTC Disclosure & News Service for viewing by the general public and regulators. The public and
OTC Markets Group may rely on the above in determining whether the Company has made adequate current information
publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933, as amended.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM